Insider Trading
| CNTX Stock | USD 0.70 0.02 2.94% |
Slightly above 55% of Context Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Context Therapeutics stock suggests that some investors are interested at this time. Context Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Context Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Context Therapeutics Director . Insider Public Trading
Read at macroaxis.com
Context Therapeutics Fundamental Analysis
We analyze Context Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Context Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Context Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Context Therapeutics stock to make a market-neutral strategy. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics with similar companies.
Peers
Context Therapeutics Related Equities
| DATS | DatChat | 3.88 | ||||
| ENSC | Ensysce Biosciences | 3.72 | ||||
| TCRX | Tscan Therapeutics | 2.34 | ||||
| DAWN | Day One | 2.08 | ||||
| BFRI | Biofrontera | 2.00 | ||||
| BOLT | Bolt Biotherapeutics | 0.36 | ||||
| LYRA | Lyra Therapeutics | 1.17 |
Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.